PMV Pharmaceuticals
PMVP
105 hedge funds and large institutions have $775M invested in PMV Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 16 reducing their positions, and 17 closing their positions.
342% more call options, than puts
Call options by funds: $6.6M | Put options by funds: $1.49M
219% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 16
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
12.57% more ownership
Funds ownership: 121.56% → 134.13% (+13%)
6% more funds holding
Funds holding: 99 → 105 (+6)
33% less capital invested
Capital invested by funds: $1.15B → $775M (-$375M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$37.9M |
| 2 |
JP Morgan Chase
New York
|
+$24.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$19.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.5M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$13.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$26.3M |
| 2 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$23.6M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$22.4M |
| 4 |
Morgan Stanley
New York
|
-$19M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$16.3M |
PMVP Hedge Fund Activity: Q2 2022 in Review
105 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q2 2022, worth a combined $775M — down 33% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PMVP positions and 17 closed out — a net gain of 8 holders — while 51 added to existing stakes and 16 trimmed.
The largest buyer was State Street, adding an estimated $37.9M. The largest seller was Cowen and Company, exiting entirely with an estimated $26.3M sold.
- 105 institutional investors held PMV Pharmaceuticals (PMVP) as of Q2 2022, up from 99 in Q1 2022.
- Funds reported $775M of PMV Pharmaceuticals stock for Q2 2022, down 33% quarter-over-quarter.
- 25 funds opened new PMV Pharmaceuticals positions in Q2 2022 and 17 closed out, a net change of +8 holders.
- The largest PMV Pharmaceuticals buyer in Q2 2022 was State Street, an estimated $37.9M added.
- The largest PMV Pharmaceuticals seller in Q2 2022 was Cowen and Company, an estimated $26.3M sold.
Based on aggregated 13F filings for Q2 2022.